Trial, reference | Number | Chemotherapy regimens | CAPOX (%) | Disease stage | Tumor location | Enrolling country | Clinical trial information |
TOSCA[1] | 3759 | CAPOX or FOLFOX4 | 35 | III, high-risk II | Colon | Italy | NCT00646607 |
SCOT[2] | 6088 | CAPOX or mFOLFOX6 | 67 | III, high-risk II | Colon | United Kingdom, Denmark, Spain, Sweden, Australia, New Zealand | NCT00749450 |
IDEA[3] | 2022 | CAPOX or mFOLFOX6 | 10 | III | Colon or rectum | France | NCT00958737 |
C80702 | 2500 | mFOLFOX6 | 0 | III, high-risk II | Colon | United States, Canada | NCT01150045 |
HORG[4] | 1115 | CAPOX or FOLFOX4 | 65 | III, high-risk II | Colon | Greece | NCT01308086 |
ACHIEVE[5] | 1313 | CAPOX or mFOLFOX6 | 75 | III | Colon | Japan | UMIN 000008543 |